April 24 (UPI) -- U.S. health officials have announced plans to spend more than $25 million on an anthrax antitoxin, as part of an emergency preparedness plan.
The Health and Human Services Department said the antitoxin -- called Anthim or obiltoxaximab -- will be purchased from New Jersey-based Elusys Therapeutics and funded by Project BioShield.